ONC Key Statistics, Chart & Performance
The current stock price of ONC is 338.78 USD. In the past month the price increased by 8.1%. In the past year, price increased by 53.84%.
ONC Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ONC. When comparing the yearly performance of all stocks, ONC is one of the better performing stocks in the market, outperforming 88.6% of all stocks.
ONC Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ONC. ONC has an average financial health and profitability rating.
ONC Financial Highlights
Over the last trailing twelve months ONC reported a non-GAAP Earnings per Share(EPS) of 64.9. The EPS increased by 215.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.28% | ||
| ROE | -0.52% | ||
| Debt/Equity | 0.23 |
ONC Forecast & Estimates
16 analysts have analysed ONC and the average price target is 347.71 USD. This implies a price increase of 2.64% is expected in the next year compared to the current price of 338.78.
For the next year, analysts expect an EPS growth of 139.04% and a revenue growth 41.33% for ONC
ONC Ownership
ONC Latest News, Press Relases and Analysis
About ONC
Company Profile
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Company Info
BEONE MEDICINES LTD-ADR
c/o BeOne Medicines I GmbH, Aeschengraben 27
Basel BASEL-STADT CH
Employees: 11075
Phone: 41616851900
BEONE MEDICINES LTD-ADR / ONC FAQ
What does BEONE MEDICINES LTD-ADR do?
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
What is the current price of ONC stock?
The current stock price of ONC is 338.78 USD. The price decreased by -0.84% in the last trading session.
Does BEONE MEDICINES LTD-ADR pay dividends?
ONC does not pay a dividend.
How is the ChartMill rating for BEONE MEDICINES LTD-ADR?
ONC has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the employee count for ONC stock?
BEONE MEDICINES LTD-ADR (ONC) currently has 11075 employees.
What is the market capitalization of ONC stock?
BEONE MEDICINES LTD-ADR (ONC) has a market capitalization of 37.49B USD. This makes ONC a Large Cap stock.
When does BEONE MEDICINES LTD-ADR (ONC) report earnings?
BEONE MEDICINES LTD-ADR (ONC) will report earnings on 2026-04-15.